GlaucomaIIT_XENNCT04727411
Analysis of Conjunctival Changes as Indicators for Ab-interno Gelatin Microstent Implantation Surgery Outcomes
A study testing XEN45 Gel stent and Trabeculectomy in people with Glaucoma and Glaucoma Open-Angle Primary, run by Hospital Clinic of Barcelona at 1 site in Spain.
Trial summary
Trabeculectomy and XEN45 gel stent implantation are glaucoma surgeries that creates an aqueous humor (AH) shunt towards the subconjunctival space (filtration bleb). Once the AH reaches the subconjunctival space, it is removed by different paths such as the trans-bleb wall route. Read more about this study
- Who is it for?
- Ages 18 to 90 years, men only
- Conditions the study is for
- Glaucoma, Glaucoma Open-Angle Primary
- What is being tested?
- XEN45 Gel stent and Trabeculectomy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 39 participants
- Where
- 1 siteSpain
- Study dates
- 1 Jan 2021to 17 Oct 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Primary open angle glaucoma
- Written informed consent
- Older than 18 years old
Who cannot join
- Patients that don't fully understand the purpose and the postoperative care
- Severe or end-stage glaucoma
- Patients with prior ocular surgery, excluding uncomplicated phacoemulsification 6 months prior to the inclusion in the study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: In Vivo Imaging and Impression Cytology Analysis of Conjunctival Changes as Potential Indicators for Ab-interno Gelatin Microstent Implantation Surgery Outcomes
Trabeculectomy and XEN45 gel stent implantation are glaucoma surgeries that creates an aqueous humor (AH) shunt towards the subconjunctival space (filtration bleb). Once the AH reaches the subconjunctival space, it is removed by different paths such as the trans-bleb wall route. For this reason, the conjunctiva is considered an essential structure that may condition the glaucoma filtering procedures outcomes. As part of the inflammatory response, an unbalanced fibrosis during the postoperative period may lead to a bleb cavity scarring and failure; for this reason, bleb massage and antifibrotic injections (i.e., 5-Fluoruracil) are frequently required as part of the postoperative care of these procedures. There have been described several risk factors, such as intraocular pressure (IOP) lowering medications, previous surgical interventions or ocular surface disease that may predispose to an early failure. These preoperative factors fail to aim to predict the surgical outcomes.
However, ocular biomarkers may overcome this limitation. There are promising studies that have analyzed the role of in vivo confocal microscopy (IVCM), anterior-segment optical coherence tomography (AS-OCT) and conjunctival cytology impression as clinical tools that may improve the filtration bleb assessment at a cellular level.
Read the detailed description
Detailed description Hypothesis
- Conjunctival biomarkers may represent a predictive factor to determine the XEN45 and trabeculectomy surgical success and outcomes
- A cellular-based analysis may help to predict postoperative pro-fibrotic changes that may lead to an early or mid-term surgery failure, and therefore it could help to improve the postoperative care of the filtering bleb.
Objective
- To evaluate the preoperative and postoperative conjunctival factors that may influence in the surgical outcomes of XEN45 gel stent compared to trabeculectomy using in vivo confocal microscopy, anterior segment optical coherence tomography and conjunctival cytology impression
- To assess the efficacy of XEN Gel stent and trabeculectomy to predict IOP, based on the morphologic characteristics of the filtering bleb
- To analyze the needling rate during the postoperative bleb management and the potential correlation to the pre and postoperative conjunctival changes and surgical success outcomes
Design Single-center, prospective, simple-blind study
Primary outcomes All the outcomes are measured pre and postoperative at each follow-up time
- In vivo confocal microscopy images: goblet cells density, dendritic cell density and stromal fibrosis
- Anterior segment optical coherence tomography: wall thickness and epithelium thickness
- Conjunctival cytology impression: dendritic cells, goblet cells
Secondary outcomes
- Intraocular pressure
- Number of IOP lowering medications
- Number of postoperative needling
Sample size calculation Based on the most assessed outcome in glaucoma surgeries and the only pilot study aiming to determine a similar outcome, to detect IOP differences between both procedures that may reflect the surgical outcomes of both procedures and therefore reflect the subconjunctival changes, accepting an alfa risk of 0.05 and a beta risk of 0.20 in a two-sided Student's T-test, 40 subjects are necessary in each group to recognize as statistically significant a difference greater than or equal to - 13,38 mm Hg in IOP, with a common standard deviation of 17%. A drop-out rate of 15% has been anticipated. If no drop-out rate is considered, the number of needed subjects is 68 (34 per group)
Method Single center, prospective, observational study of primary open angle glaucoma and uncontrolled intraocular pressure, progression of the disease confirmed by visual field examination that require either XEN gel stent implantation or trabeculectomy.
Preoperative examinations
- Medial records including ophthalmic procedures, other ocular diseases, intraocular pressure while on treatment, target pressure, visual field, detailed description of the optic disc, both preoperative and postoperative
- Glaucoma staging: peripapillary retinal nerve fiber layer, visual field (baseline, 3 moths and 6 months)
- Ocular biomarkers
- In vivo confocal microscopy (baseline, 3 moths and 6 months)
- Conjunctival impression cytology (baseline, 3 moths and 6 months)
A specific case report form (CRF) was designed with all variables and data required for the study, including potential complications
Surgery. Patients were assigned either to trabeculectomy or XEN stent implantation
Trabeculectomy: the surgical technique is as follows: retro/peribulbar o subtenon's anesthesia, superior corneal traction suture, phacoemulsification through 2.2 with in-the-bag IOL implantation, a fornix-based conjunctival flap, sufficient but not excessive cauterization, application mitomycin-C (MMC) 0,2 mg/ml for 2 minutes under the conjunctiva, then MMC was washed out with 100 ml of saline solution, then a scleral flap (4x3 mm in the trabeculectomy) is dissected. A sclerectomy with punch and peripheral iridectomy were performed, and suture nylon 10/00 sutures was used to place 3 or 4 stiches in the scleral flap
XEN gel stent: a clear cornea incision in the inferotemporal quadrant was performed, injecting the XEN 45 device into the superonasal quadrant using an ab interno approach. Approximately 15 min before inserting the implant, 0.1 ml of a MMC solution (0.01%) was injected into the superior conjunctiva. Both stand-alone and combined phaco-glaucoma procedures were used.
Post-operative treatment. All patients instilled ofloxacin antibiotic every 6 hours for 1 week, dexamethasone (every 2 hours for 1 month, every 4-6 hours on the second month and tapered during the third month according to surgeon's instructions). Atropine was also used when clinical finds recommended its use. Subconjunctival injections of anti-fibrotic agents (5-FU) and/or bleb needling were allowed and performed at the discretion of the surgeon
Statistical analysis
- Descriptive statistics, including mean and standard deviation for normally distributed variables and median and interquartile range for non-normally distributed variables, previous checked using Shapiro-Wilk test.
- Logistic regression models to evaluate the correlation with preoperative and postoperative factors and needling rate, surgical success (IOP < 18 mm Hg), and ocular biomarkers. The results will be reported as odds ratio (OR).
- All the reported values will be considered statistically significant at two-tailed p <0.05
- Conditions
- Glaucoma, Glaucoma Open-Angle Primary
- Being tested
- XEN45 Gel stent, Trabeculectomy
- Keywords
- Gel stent, Trabeculectomy, In vivo confocal microscopy, Conjunctival impression cytology, Anterior segment optical coherence tomography
- Medical subject headings
- Glaucoma, Glaucoma, Open-Angle
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
XEN45 Gel stentProcedure or surgery
XEN Gel stent implantation either combined or as a stand-alone procedure
TrabeculectomyProcedure or surgery
XEN Gel stent implantation either combined or as a stand-alone procedure
| Study group | Role | What they receive |
|---|---|---|
| Gel Stent implantation | Experimental | XEN gel stent: a clear cornea incision in the inferotemporal quadrant was performed, injecting the XEN 45 device into the superonasal quadrant using an ab interno approach. Approximately 15 min before inserting the implant, 0.1 ml of a MMC solution (0.01%) was injected into the superior conjunctiva. Both stand-alone and combined phaco-glaucoma procedures were used. Receives: Procedure: XEN45 Gel stent |
| Trabeculectomy | Experimental | Trabeculectomy: the surgical technique is as follows: retro/peribulbar o subtenon's anesthesia, superior corneal traction suture, phacoemulsification through 2.2 with in-the-bag IOL implantation, a fornix-based conjunctival flap, sufficient but not excessive cauterization, application MMC 0,2 mg/ml for 2 minutes under the conjunctiva, then MMC was washed out with 100 ml of saline solution, then a scleral flap (4x3 mm in the trabeculectomy) is dissected. A sclerectomy with punch and peripheral iridectomy were performed, and suture nylon 10/00 sutures was used to place 3 or 4 stiches in the scleral flap Receives: Procedure: Trabeculectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
In vivo confocal microscopy of the filtering bleb
Increase of the mean microcysts density (MMD): number of cysts/mm2
Measured: Preoperative to 6 months operative
Anterior segment optical coherence tomography microscopy of the filtering bleb
Differences in thickness of the conjunctival epithelial surface and the bleb wall, in micrometers
Measured: Preoperative to 6 months operative
Conjunctival impression cytology of the filtering bleb
Increase in the percentage of goblet cells biomarkers
Measured: Preoperative to 6 months operative
Secondary outcomes (2)
Intraocular pressure
Difference of intraocular pressure, in mm Hg
Measured: Preoperative to 6 months visit, at each follow-up visit
Glaucoma medications
Difference between the number of glaucoma medications before and after each surgery
Measured: Preoperative to 6 months visit, at each follow-up visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2021
- Study start1 Jan 2021
- Primary completion31 May 2022
- Study completion17 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for GlaucomaStudies of the same condition, open and under way.
- More trials run by Hospital Clinic of BarcelonaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 39 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hospital Clinic of Barcelona
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Néstor Ventura, Hospital Clinic of Barcelona
- Investigators
- Marta Pazos, MD, PhD, Principal investigator, Hospital Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04727411
- Sponsor's protocol ID
- HCB/2019/0035
- Acronym
- IIT_XEN
- Status last verified
- Jan 2024
- First submitted
- 16 Jan 2021
- Last updated
- 9 Jan 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Ventura-Abreu N, Molins B, Guerra-Meniconi J, Labay-Tejado S, Porto S, Muniesa MJ, Milla E, Pazos M. Longitudinal analysis of XEN45 gel stent bleb morphology using bleb grading scales, anterior segment-OCT, in vivo confocal microscopy, and impression cytology. Graefes Arch Clin Exp Ophthalmol. 2026 Jan;264(1):207-218. doi: 10.1007/s00417-025-06952-0. Epub 2025 Oct 3.
PubMed 41042361
Study at a glance
From the registry record, last updated by the sponsor on 9 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- In Vivo Imaging and Impression Cytology Analysis of Conjunctival Changes as Potential Indicators for Ab-interno Gelatin Microstent Implantation Surgery Outcomes
- ClinicalTrials.gov ID
- NCT04727411
- Acronym / sponsor ID
- IIT_XEN / HCB/2019/0035
- Conditions
- Glaucoma, Glaucoma Open-Angle Primary
- Keywords
- Gel stent, Trabeculectomy, In vivo confocal microscopy, Conjunctival impression cytology, Anterior segment optical coherence tomography
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 39 participants (actual)
- Lead sponsor
- Hospital Clinic of BarcelonaUniversity, hospital or other
- Study start
- 1 Jan 2021 (actual)
- Primary completion
- 31 May 2022 (actual)
- Study completion
- 17 Oct 2022 (actual)
- First posted
- 27 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Trabeculectomy and XEN45 gel stent implantation are glaucoma surgeries that creates an aqueous humor (AH) shunt towards the subconjunctival space (filtration bleb). Once the AH reaches the subconjunctival space, it is removed by different paths such as the trans-bleb wall route. For this reason, the conjunctiva is considered an essential structure that may condition the glaucoma filtering procedures outcomes. As part of the inflammatory response, an unbalanced fibrosis during the postoperative period may lead to a bleb cavity scarring and failure; for this reason, bleb massage and antifibrotic injections (i.e., 5-Fluoruracil) are frequently required as part of the postoperative care of these procedures. There have been described several risk factors, such as intraocular pressure (IOP) lowering medications, previous surgical interventions or ocular surface disease that may predispose to an early failure. These preoperative factors fail to aim to predict the surgical outcomes.
However, ocular biomarkers may overcome this limitation. There are promising studies that have analyzed the role of in vivo confocal microscopy (IVCM), anterior-segment optical coherence tomography (AS-OCT) and conjunctival cytology impression as clinical tools that may improve the filtration bleb assessment at a cellular level.
Detailed description
Detailed description Hypothesis
- Conjunctival biomarkers may represent a predictive factor to determine the XEN45 and trabeculectomy surgical success and outcomes
- A cellular-based analysis may help to predict postoperative pro-fibrotic changes that may lead to an early or mid-term surgery failure, and therefore it could help to improve the postoperative care of the filtering bleb.
Objective
- To evaluate the preoperative and postoperative conjunctival factors that may influence in the surgical outcomes of XEN45 gel stent compared to trabeculectomy using in vivo confocal microscopy, anterior segment optical coherence tomography and conjunctival cytology impression
- To assess the efficacy of XEN Gel stent and trabeculectomy to predict IOP, based on the morphologic characteristics of the filtering bleb
- To analyze the needling rate during the postoperative bleb management and the potential correlation to the pre and postoperative conjunctival changes and surgical success outcomes
Design Single-center, prospective, simple-blind study
Primary outcomes All the outcomes are measured pre and postoperative at each follow-up time
- In vivo confocal microscopy images: goblet cells density, dendritic cell density and stromal fibrosis
- Anterior segment optical coherence tomography: wall thickness and epithelium thickness
- Conjunctival cytology impression: dendritic cells, goblet cells
Secondary outcomes
- Intraocular pressure
- Number of IOP lowering medications
- Number of postoperative needling
Sample size calculation Based on the most assessed outcome in glaucoma surgeries and the only pilot study aiming to determine a similar outcome, to detect IOP differences between both procedures that may reflect the surgical outcomes of both procedures and therefore reflect the subconjunctival changes, accepting an alfa risk of 0.05 and a beta risk of 0.20 in a two-sided Student's T-test, 40 subjects are necessary in each group to recognize as statistically significant a difference greater than or equal to - 13,38 mm Hg in IOP, with a common standard deviation of 17%. A drop-out rate of 15% has been anticipated. If no drop-out rate is considered, the number of needed subjects is 68 (34 per group)
Method Single center, prospective, observational study of primary open angle glaucoma and uncontrolled intraocular pressure, progression of the disease confirmed by visual field examination that require either XEN gel stent implantation or trabeculectomy.
Preoperative examinations
- Medial records including ophthalmic procedures, other ocular diseases, intraocular pressure while on treatment, target pressure, visual field, detailed description of the optic disc, both preoperative and postoperative
- Glaucoma staging: peripapillary retinal nerve fiber layer, visual field (baseline, 3 moths and 6 months)
- Ocular biomarkers
- In vivo confocal microscopy (baseline, 3 moths and 6 months)
- Conjunctival impression cytology (baseline, 3 moths and 6 months)
A specific case report form (CRF) was designed with all variables and data required for the study, including potential complications
Surgery. Patients were assigned either to trabeculectomy or XEN stent implantation
Trabeculectomy: the surgical technique is as follows: retro/peribulbar o subtenon's anesthesia, superior corneal traction suture, phacoemulsification through 2.2 with in-the-bag IOL implantation, a fornix-based conjunctival flap, sufficient but not excessive cauterization, application mitomycin-C (MMC) 0,2 mg/ml for 2 minutes under the conjunctiva, then MMC was washed out with 100 ml of saline solution, then a scleral flap (4x3 mm in the trabeculectomy) is dissected. A sclerectomy with punch and peripheral iridectomy were performed, and suture nylon 10/00 sutures was used to place 3 or 4 stiches in the scleral flap
XEN gel stent: a clear cornea incision in the inferotemporal quadrant was performed, injecting the XEN 45 device into the superonasal quadrant using an ab interno approach. Approximately 15 min before inserting the implant, 0.1 ml of a MMC solution (0.01%) was injected into the superior conjunctiva. Both stand-alone and combined phaco-glaucoma procedures were used.
Post-operative treatment. All patients instilled ofloxacin antibiotic every 6 hours for 1 week, dexamethasone (every 2 hours for 1 month, every 4-6 hours on the second month and tapered during the third month according to surgeon's instructions). Atropine was also used when clinical finds recommended its use. Subconjunctival injections of anti-fibrotic agents (5-FU) and/or bleb needling were allowed and performed at the discretion of the surgeon
Statistical analysis
- Descriptive statistics, including mean and standard deviation for normally distributed variables and median and interquartile range for non-normally distributed variables, previous checked using Shapiro-Wilk test.
- Logistic regression models to evaluate the correlation with preoperative and postoperative factors and needling rate, surgical success (IOP < 18 mm Hg), and ocular biomarkers. The results will be reported as odds ratio (OR).
- All the reported values will be considered statistically significant at two-tailed p <0.05
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Gel Stent implantation | Experimental | Procedure: XEN45 Gel stentXEN gel stent: a clear cornea incision in the inferotemporal quadrant was performed, injecting the XEN 45 device into the superonasal quadrant using an ab interno approach. Approximately 15 min before inserting the implant, 0.1 ml of a MMC solution (0.01%) was injected into the superior conjunctiva. Both stand-alone and combined phaco-glaucoma procedures were used. |
| Trabeculectomy | Experimental | Procedure: TrabeculectomyTrabeculectomy: the surgical technique is as follows: retro/peribulbar o subtenon's anesthesia, superior corneal traction suture, phacoemulsification through 2.2 with in-the-bag IOL implantation, a fornix-based conjunctival flap, sufficient but not excessive cauterization, application MMC 0,2 mg/ml for 2 minutes under the conjunctiva, then MMC was washed out with 100 ml of saline solution, then a scleral flap (4x3 mm in the trabeculectomy) is dissected. A sclerectomy with punch and peripheral iridectomy were performed, and suture nylon 10/00 sutures was used to place 3 or 4 stiches in the scleral flap |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Primary open angle glaucoma
- Written informed consent
- Older than 18 years old
Key exclusion criteria (3 listed)
- Patients that don't fully understand the purpose and the postoperative care
- Severe or end-stage glaucoma
- Patients with prior ocular surgery, excluding uncomplicated phacoemulsification 6 months prior to the inclusion in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| XEN45 Gel stentXEN Gel stent implantation either combined or as a stand-alone procedure | Procedure or surgery | Gel Stent implantation |
| TrabeculectomyXEN Gel stent implantation either combined or as a stand-alone procedure | Procedure or surgery | Trabeculectomy |
Primary outcome
In vivo confocal microscopy of the filtering bleb
Time frame: Preoperative to 6 months operative
Increase of the mean microcysts density (MMD): number of cysts/mm2
Anterior segment optical coherence tomography microscopy of the filtering bleb
Time frame: Preoperative to 6 months operative
Differences in thickness of the conjunctival epithelial surface and the bleb wall, in micrometers
Conjunctival impression cytology of the filtering bleb
Time frame: Preoperative to 6 months operative
Increase in the percentage of goblet cells biomarkers
2 secondary outcomes
Intraocular pressure
Time frame: Preoperative to 6 months visit, at each follow-up visit
Glaucoma medications
Time frame: Preoperative to 6 months visit, at each follow-up visit
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jan 2024.
- Derived from this study: PubMed 41042361Ventura-Abreu N, Molins B, Guerra-Meniconi J, Labay-Tejado S, Porto S, Muniesa MJ, Milla E, Pazos M. Longitudinal analysis of XEN45 gel stent bleb morphology using bleb grading scales, anterior segment-OCT, in vivo confocal microscopy, and impression cytology. Graefes Arch Clin Exp Ophthalmol. 2026 Jan;264(1):207-218. doi: 10.1007/s00417-025-06952-0. Epub 2025 Oct 3.
Related trials for Glaucoma
Recruiting
Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
Glaucoma, Ocular Hypertension
Not yet recruiting
AI-Assisted vs Conventional Teleglaucoma Referral
Glaucoma
Recruiting
Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment
Retinitis Pigmentosa (RP), Rod Cone Dystrophy
Recruiting
Automated Applanation Tonometry - Updated
Glaucoma, Glaucoma, Suspect
RecruitingPhase 2
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Marta Pazos, MD, PhD principal investigator
Hospital Clinic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing XEN45 Gel stent and Trabeculectomy in people with Glaucoma and Glaucoma Open-Angle Primary, run by Hospital Clinic of Barcelona at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
In vivo confocal microscopy of the filtering bleb (time frame: Preoperative to 6 months operative). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04727411, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jan 2024.